GTCR Announces Partnership with Ed Fiorentino to Form Actient Pharmaceuticals

CHICAGO--(Business Wire)--
GTCR, one of the nation's leading private equity firms, today announced that it
has entered into a partnership with Ed Fiorentino to form Actient
Pharmaceuticals, LLC ("Actient"). The new company, headquartered in Deerfield,
Illinois, will focus on acquiring and operating specialty pharmaceutical
companies and products. Target opportunities include products which are already
approved or currently marketed, as well as late-stage development drugs. GTCR
plans to invest up to $200 million of equity capital to support management's
strategy. Mr. Fiorentino will serve as Chief Executive Officer of Actient.

Ed Fiorentino is a former corporate officer and 22-year veteran of Abbott
Laboratories (NYSE:ABT). His senior-level management experience at Abbott
includes Corporate Vice President of Pharmaceutical Commercial Operations where
he was responsible for all U.S. sales, marketing and new product planning. He
also served as Senior Vice President and President, Abbott Diabetes Care,
leading Abbott's global device business in this area. Most recently, Ed was
Executive Vice President of TAP Pharmaceutical, an Abbott joint venture with
Takeda Pharmaceutical.

"We are excited to partner with Ed to build an industry-leading specialty
pharmaceutical company focused on delivering clinically meaningful products to
patients," said GTCR Principal Dean Mihas. "We believe Ed`s combination of
industry expertise and operational experience makes him an ideal partner as GTCR
commits to another platform in the specialty pharmaceutical industry."

"I am thrilled about the opportunity to build a significant global specialty
pharmaceutical company," said Mr. Fiorentino. "GTCR has a long history of
backing experienced managers and providing them with the resources and support
required to build successful companies through both organic growth and
acquisitions. GTCR`s very successful track record with companies like Ovation
Pharmaceuticals and Graceway Pharmaceuticals make them an ideal partner with
whom to form Actient."

"We continue to be enthusiastic about investing capital in the pharmaceutical
industry," added Ben Daverman, Vice President at GTCR. "We are actively looking
for acquisitions and see a number of compelling investment opportunities in the
market today. Working with Ed, we are in a unique position to evaluate and
pursue these assets."

GTCR`s investment in Actient will be made from GTCR Fund IX LP, a private equity
fund with $2.75 billion of committed capital.

About Actient Pharmaceuticals

Actient Pharmaceuticals is a specialty pharmaceutical company focused on
therapeutics to improve patient outcomes. The company was formed to acquire
specialty pharmaceutical companies and products with a focus on select physician
specialties. For more information, contact Actient Pharmaceuticals at
847.778.1876.

About GTCR

Founded in 1980, GTCR Golder Rauner, LLC is a leading private equity investment
firm and long-term strategic partner for outstanding management teams. The
Chicago-based firm pioneered the investment strategy of identifying and
partnering with exceptional executives to acquire and build companies through a
combination of acquisitions and strong internal growth. GTCR currently manages
more than $8 billion of equity capital invested in a wide range of companies and
industries. More information about GTCR can be found at www.gtcr.com.

At GTCR:
Dean Mihas, 312.382.2204
Ben Daverman, 312.382.2069
or
At Weber Shandwick:
Sean Mogle, 312.988.2046

Copyright Business Wire 2009